Immune checkpoint inhibitors, including nivolumab and pembrolizumab, which target PD-1, along with therapies aimed at PD-L1, including atezolizumab, have demonstrated significant therapeutic efficacy in the management of melanoma, NSCLC, and renal cell carcinoma [116]. Here, PDCD1 is linked to non-small cell lung carcinoma.